NO983823L - FremgangsmÕte og preparat for inhibering av irreversible celleforandringer pÕ grunn av stress - Google Patents

FremgangsmÕte og preparat for inhibering av irreversible celleforandringer pÕ grunn av stress

Info

Publication number
NO983823L
NO983823L NO983823A NO983823A NO983823L NO 983823 L NO983823 L NO 983823L NO 983823 A NO983823 A NO 983823A NO 983823 A NO983823 A NO 983823A NO 983823 L NO983823 L NO 983823L
Authority
NO
Norway
Prior art keywords
stress
preparation
changes due
compounds
cellular changes
Prior art date
Application number
NO983823A
Other languages
English (en)
Other versions
NO983823D0 (no
Inventor
Guy Miller
Lillian Lou
John Nakamura
Original Assignee
Galileo Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galileo Lab Inc filed Critical Galileo Lab Inc
Publication of NO983823D0 publication Critical patent/NO983823D0/no
Publication of NO983823L publication Critical patent/NO983823L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Formuleringer av naturlig forekommende fysiologisk akseptable forbindelser og deres derivater for behandling av cellulært stress, spesielt hypoksi, ved administrasjon av formuleringene, omfattende for det meste puriner, sukkere, aminosyrer og fysiologisk akseptable derivater derav, alene eller i kombinasjon med hverandre og med andre forbindelser, spesielt elektronakseptorforbindelser, kan tiden til irreversible celle- endringer, spesielt mortalitet, sterkt forlenges.
NO983823A 1996-02-23 1998-08-20 FremgangsmÕte og preparat for inhibering av irreversible celleforandringer pÕ grunn av stress NO983823L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/607,022 US5801159A (en) 1996-02-23 1996-02-23 Method and composition for inhibiting cellular irreversible changes due to stress
PCT/US1997/002945 WO1997030713A1 (en) 1996-02-23 1997-02-20 Method and composition for inhibiting cellular irreversible changes due to stress

Publications (2)

Publication Number Publication Date
NO983823D0 NO983823D0 (no) 1998-08-20
NO983823L true NO983823L (no) 1998-10-01

Family

ID=24430472

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983823A NO983823L (no) 1996-02-23 1998-08-20 FremgangsmÕte og preparat for inhibering av irreversible celleforandringer pÕ grunn av stress

Country Status (7)

Country Link
US (1) US5801159A (no)
EP (1) EP0935466A1 (no)
JP (1) JP2000506834A (no)
AU (1) AU1974997A (no)
CA (1) CA2247461A1 (no)
NO (1) NO983823L (no)
WO (1) WO1997030713A1 (no)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6338963B1 (en) 1994-07-25 2002-01-15 Neotherapeutics, Inc. Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
CA2302687A1 (en) * 1997-09-11 1999-03-18 Oxigene, Inc. Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases
US6303617B1 (en) 1998-05-04 2001-10-16 Neotherapeutics, Inc. Serotonin-like 9-substituted hypoxanthine and methods of use
DE69904257T2 (de) * 1999-01-20 2003-04-17 N.V. Nutricia, Zoetermeer Säuglingsnährpräparat
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US6426362B1 (en) * 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
US6288069B1 (en) 1999-11-16 2001-09-11 Neotherapeutics, Inc. Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue
US6407237B1 (en) 2001-02-21 2002-06-18 Neotherapeutics, Inc. Crystal forms of 9-substituted hypoxanthine derivatives
US6849735B1 (en) * 2000-06-23 2005-02-01 Merck Eprova Ag Methods of synthesis for 9-substituted hypoxanthine derivatives
US6630490B2 (en) 2000-07-07 2003-10-07 Neotherapeutics, Inc. Methods for treatment of disease-induced peripheral neuropathy and related conditions
US7034054B2 (en) * 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US6759427B2 (en) * 2001-04-20 2004-07-06 Spectrum Pharmaceuticals, Inc. Synthesis and methods of use of tetrahydroindolone analogues and derivatives
CA2453381A1 (en) * 2001-07-10 2003-01-23 Massachusetts Institute Of Technology Methods for ex vivo propagation of somatic stem cells
AU2003228212A1 (en) * 2002-02-15 2003-09-09 Gracy G. Crane Hepatocyte precursor cell lines
EP1352910A1 (en) * 2002-04-10 2003-10-15 Grünenthal GmbH New analogs of nitrobenzylthioinosine
US20030236217A1 (en) * 2002-05-21 2003-12-25 Shalwitz Robert A. Treatment of mucositis
MXPA05001202A (es) 2002-07-29 2005-11-23 Hawaii Biotech Inc Analogos carotenoides estructurales para la inhibicion y mejora de la enfermedad.
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US7763649B2 (en) * 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US7723327B2 (en) * 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
EP1563063A2 (en) * 2002-11-07 2005-08-17 Rensselaer Polytechnic Institute Calmodulin independent activation of nitric oxide synthase by nadph analogs
US7199110B2 (en) * 2002-12-30 2007-04-03 Purdue Research Foundation Method of treatment for spinal cord injury
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
WO2005102356A1 (en) * 2004-04-14 2005-11-03 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
ME01072B (me) 2004-05-26 2012-10-20 Inotek Pharmaceuticals Corp Derivati purina kao agonisti receptora adenozina a1 i postupci za njihovu upotrebu
US7655465B2 (en) * 2004-06-07 2010-02-02 Massachusetts Institute Of Technology Methods for ex vivo propagation of somatic hair follicle stem cells
US20050276762A1 (en) * 2004-06-15 2005-12-15 Tapas Das Topical compositions containing 5'-adenosine-diphosphate ribose
JP4724810B2 (ja) * 2005-03-02 2011-07-13 財団法人ヒューマンサイエンス振興財団 ポリ（ａｄｐ−リボース）代謝のバイオマーカーとしてのリボシルアデノシンおよびリボシルイノシン
US20060270590A1 (en) 2005-03-29 2006-11-30 Lockwood Samuel F Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
EA035619B1 (ru) * 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Композиции для использования в способе лечения митохондриальных нарушений
US7824912B2 (en) * 2005-06-23 2010-11-02 Massachusetts Institute Of Technology Methods for ex vivo propagation of adult hepatic stem cells
ITRM20050391A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti analoghi della 6-tioguanosina trifosfato, loro uso in campo medico e procedimento per la loro preparazione.
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
AU2007234006A1 (en) * 2006-03-31 2007-10-11 Adenobio N.V. Compositions, methods, and kits using adenosine and inosine in combination for diagnosis and treatment
PL2220030T3 (pl) 2007-11-06 2016-07-29 Bioelectron Tech Corp Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych
EP2237664A4 (en) 2008-01-08 2013-05-22 Edison Pharmaceuticals Inc (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
EP2303824B1 (en) * 2008-06-25 2015-03-25 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
CA2740773A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
WO2010051277A1 (en) 2008-10-28 2010-05-06 Edison Pharmaceuticals, Inc. Process for the production of alpha-tocotrienol and derivatives
CA2777479C (en) 2009-04-28 2017-10-17 Ptc Therapeutics, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
NO2470168T3 (no) * 2009-08-26 2018-06-30
JP2013516495A (ja) 2010-01-11 2013-05-13 イノテック ファーマシューティカルズ コーポレイション 眼圧を低下させる組合せ、キット、および方法
JP2013523739A (ja) 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション Ｎ６−シクロペンチルアデノシン（ｃｐａ）、ｃｐａ誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法
WO2012019160A1 (en) * 2010-08-05 2012-02-09 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
CA2842486C (en) 2011-07-19 2022-09-06 Edison Pharmaceuticals, Inc. Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
SMT201700377T1 (it) 2012-01-26 2017-09-07 Inotek Pharmaceuticals Corp Polimorfi anidri di (2r,3s,4r,5r)-5-(6-(ciclopentilammino)-9h-purin-9-il)-3,4- diidrossitetraidrofuran-2-il)}metil nitrato e processi di sua preparazione
PL227045B1 (pl) * 2012-09-14 2017-10-31 Blirt Spółka Akcyjna Płyn do przechowywania narządów w czasie zabiegów chirurgicznych, zwłaszcza transplantacji.
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
HUE058877T2 (hu) 2014-12-16 2022-09-28 Ptc Therapeutics Inc (R)-2-hidroxi-2-metil-4-(2,4,5-trimetil-3,6-dioxociklohexa-1,4-dienil)butánamid polimorf és amorf alakjai
JP7117241B2 (ja) 2015-12-16 2022-08-12 ピーティーシー セラピューティクス， インコーポレイテッド 混合されたトコール組成物からアルファ－トコトリエノールを富化するための改良された方法
EP3389646A1 (en) 2015-12-17 2018-10-24 BioElectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
HUE066196T2 (hu) 2018-10-17 2024-07-28 Ptc Therapeutics Inc 2,3,5-trimetil-6-nonilciklohexa-2,5-dién-1,4-dion alfa-szinukleinopátiák, tauopátiák és egyéb rendellenességek szuppresszálására és kezelésére
EP4366700A1 (en) 2021-07-08 2024-05-15 PTC Therapeutics, Inc. Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575498A (en) * 1983-07-21 1986-03-11 Duke University Method for restoring depleted purine nucleotide pools
US5066578A (en) * 1989-12-21 1991-11-19 The Regents Of The University Of California Long-term preservation of organs for transplantation
US5145771A (en) * 1990-04-12 1992-09-08 The University Of North Carolina At Chapel Hill Rinse solution for organs and tissues
US5320846A (en) * 1991-04-17 1994-06-14 New England Deaconess Hospital Corp. Method and composition for testing patients with metabolic depleting diseases
AU664074B2 (en) * 1992-06-26 1995-11-02 Torii Pharmaceutical Co., Ltd. Organ preserving fluid
US5405742A (en) * 1993-07-16 1995-04-11 Cyromedical Sciences, Inc. Solutions for tissue preservation and bloodless surgery and methods using same

Also Published As

Publication number Publication date
AU1974997A (en) 1997-09-10
CA2247461A1 (en) 1997-08-28
WO1997030713A1 (en) 1997-08-28
JP2000506834A (ja) 2000-06-06
US5801159A (en) 1998-09-01
EP0935466A1 (en) 1999-08-18
NO983823D0 (no) 1998-08-20

Similar Documents

Publication Publication Date Title
NO20081365L (no) Ny krystallinsk form av et pyridazino[4,5-b]indolderivat
WO2009086457A3 (en) 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions
NO960049L (no) Fremstilling og stabilisering av celler
ES2176502T3 (es) Derivados de hidroxilamina utiles para mejorar la pproduccion de chaperonas moleculares su su preparacion.
KR20170102861A (ko) 식물 추출물의 혼합물 또는 상기 식물 속에 함유된 분자의 혼합물을 함유하는 조성물, 및 당질 및/또는 지질 대사를 조절하기 위한 용도
ES2048560T3 (es) Fibra dietetica, su procedimiento y composicion con actividad fisiologica que lo contiene como ingrediente activo.
DE60041637D1 (de) Augenbehandlung unter verwendung von cyclosporin a derivaten
FI960750A0 (fi) Hermon kasvutekijän farmaseuttiset formulaatiot
NO20005155L (no) Forbedring av antistoff-cytokin fusjon protein-medierte immunoresponser ved ko-administrasjon med angiogeneseinhibator
AR037971A1 (es) Preparacion liofilizada que contiene un anticuerpo contra el receptor egf
NO954878L (no) Pyrrolderivater
Schramm et al. Natural products as potential human ether-a-go-go-related gene channel inhibitors–screening of plant-derived alkaloids
WO2002017898A3 (en) Compositions and methods for inducing vasorelaxation
DK0563085T3 (da) Hidtil ukendte præparater
NO20056000L (no) Vevsbeskyttende cytokiner for beskyttelse, gjenoppbygging og okning av responsivceller, vev og organer med et utvidet terapeutisk vindu
KR960704561A (ko) 바이러스성 유발 종양의 예방과 치료용 조성물
FR2612775A1 (fr) Compositions pour la prevention et le traitement de la degenerescence cutanee
DK0673250T3 (da) Ophthalmiske præparater omfattende emedastin og deres anvendelse til behandling af allergisk conjunctivitis
NO941097L (no) Hudregenererende kosmetisk preparat
DK578789D0 (da) Pyrrolidin-2-carboxylsyre-derivater med psykotrop virkning, deres fremstilling og anvendelse
Wu et al. Cardiac effects of the extract and active components of radix stephaniae tetrandrae: I. Electrically-induced intracellular calcium transient and protein release during the calcium paradox
ATE481976T1 (de) Zusammensetzungen aus organischen extrakten von geum japonicum thunb var. und ihre verwendung
Van Belle et al. The effect of calcium antagonists and of mioflazine on the release of purine nucleosides after 10 min of ischemia in the iated guinea pig heart
WO2002078600A3 (en) γεRACK PEPTIDE COMPOSITION AND METHOD FOR PROTECTION AGAINST TISSUE DAMAGE DUE TO ISCHEMIA
Pestre et al. Effect of bepridil treatment on myocardial susceptibility to global ischemia in chronically infacrted rat hearts

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application